Expert Opinion on Investigational Drugs

Kinase insert domain-containing receptor kinase inhibitors as anti-angiogenic agents
pp. 737-745(9)
Authors: Hartman G.D.; Fraley M.E.; Bilodeau M.T.

Epigenetic cancer therapies: DNA methyltransferase inhibitors
pp. 747-754(8)
Authors: Brown R.; Strathdee G.

Anti-epidermal growth factor receptor drugs in cancer therapy
pp. 755-768(14)
Authors: Tortora G.; Ciardiello F.

Novel treatments and therapies in development for pancreatic cancer
pp. 769-786(18)
Authors: Löhr M.; Günzburg W.H.; Salmons B.

Dopamine receptor agonists for treating prolactinomas
pp. 787-800(14)
Authors: Colao A.; Somma C.d.; Lombardi G.; Pivonello R.; Sarno A.d.

Anti-emetics in development
pp. 801-805(5)
Author: Loewen P.S.

Next generation antihistamines: therapeutic rationale, accomplishments and advances
pp. 807-817(11)
Authors: Casale T.B.; Oppenheimer J.J.

Nephrological and obstetric complications of the antiphospholipid syndrome
pp. 819-829(11)
Authors: Nickolas T.L.; Radhakrishnan J.; Isom R.

Cholesterol absorption inhibitors in development as potential therapeutics
pp. 831-835(5)
Authors: Takekoshi N.; Kajinami K.

ZD1839: targeting the epidermal growth factor receptor in cancer therapy
pp. 837-849(13)
Author: Herbst R.S.

Agalsidase alfa – a preparation for enzyme replacement therapy in Anderson–Fabry disease
pp. 851-858(8)
Author: Beck M.

Peramivir (BCX-1812, RWJ-270201): potential new therapy for influenza
pp. 859-869(11)
Authors: Smee D.F.; Sidwell R.W.

Recent and ongoing clinical trials for treating colorectal cancer
pp. 871-880(10)
Authors: III A.B.B.; Mulcahy M.F.